SERM
The first 29 amino acids of natural GHRH; physiology studies describe physiological (pulsatile) GH release patterns. Formerly FDA-approved for pediatric GHD; no longer marketed in the US.
Regulatory status (as of Sept 2026)
Previously FDA-approved (Geref), since discontinued in the US; compounded sermorelin is not an FDA-approved product.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote2 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Sermorelin is a compound whose development or US marketing has been discontinued. The first 29 amino acids of natural GHRH; physiology studies describe physiological (pulsatile) GH release patterns.
| Half-life | 10-20 minutes |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Discontinued |
| Dosing | Published research: No published human dosing detailsDiagnostic: 1 µg/kg IV single dose; pediatric GHD treatment: 30 µg/kg SC once daily at bedtime.Community-reportedCommunity-reported: 100–300 mcg, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a short copy of the hormone that tells the pituitary gland to release growth hormone. GHRH fragment (GRF 1-29) that stimulates growth hormone secretion from the anterior pituitary (review, Prakash 1999).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedCommonly reported doses range from 100 to 300 mcg (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Sermorelin | 10-20 minutes | Subcutaneous injection | Discontinued |
| CJC-1295 (no DAC) | No published PK data found | Subcutaneous injection | Preclinical (animal) |
| CJC-1295 (with DAC) | 6-8 days | Subcutaneous injection | Phase 1 / early human |
| GHRP-2 | No published PK data found | Subcutaneous injection | Phase 1 / early human |
| GHRP-6 | No published PK data found | Subcutaneous injection | Phase 1 / early human |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Growth Hormone category. View All Growth Hormone Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.